Publications by authors named "Anthony Gill"

Background: FXYD3 is a Na/K-ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo-naive patients with surgically-resected PDAC at a single centre (1993-2014).

Method: FXYD3 expression was assessed in tumour specimens using immunohistochemistry.

View Article and Find Full Text PDF

Kidney fibrosis is the common pathological pathway in progressive chronic kidney disease (CKD), and current treatments are largely ineffective. The C-X-C chemokine receptor 4 (CXCR4) is crucial to fibrosis development. By using neural cell adhesion molecules as scaffolds with binding loops that mimic the shape of shark antibodies, fully humanized single-domain i-bodies have been developed.

View Article and Find Full Text PDF

Introduction: Intraductal papillary mucinous neoplasms (IPMNs) are diverse premalignant tumors of the pancreas. They progress stepwise from adenoma to carcinoma and offer an opportunity for intervention prior to malignant transformation into pancreatic ductal adenocarcinoma (PDAC). The current study aimed to identify differentially expressed genes (DEGs) in invasive PDAC-associated IPMN vs.

View Article and Find Full Text PDF

Compsanthias new genus is described for Anthias ventralis Randall (type species) and A. hawaiiensis Randall, which had been previously classified in the genus Pseudanthias Bleeker. Compsanthias is distinguished from other anthiadid genera in having the following combination of characters: dorsal-fin rays X,16-18, usually X,17; anal-fin rays III,9-10, usually III,9; pectoral-fin rays 14-16, usually 15, most rays branched; branched caudal-fin rays 7+6; tubed scales in lateral series 39-46.

View Article and Find Full Text PDF

Medullary thyroid carcinoma (MTC) can either be sporadic, often via mutually exclusive RET or RAS alterations, or inherited via a RET germline alteration. Germline testing is recommended for all patients diagnosed with MTC. RAS p.

View Article and Find Full Text PDF

Background: Lymph node yield (LNY) is a validated quality control parameter in colorectal cancer surgery, with >12 nodes reflecting an adequate oncological resection. No formal guidelines exist in the context of central and lateral compartment lymph node dissection for papillary thyroid cancer (PTC). This study aimed to investigate the association between LNY and regional recurrence in PTC patients, and to define a threshold LNY that indicates adequate compartmental lymphadenectomy.

View Article and Find Full Text PDF

Background: Neoadjuvant chemotherapy (NAC) can provide improved survival outcomes in pancreatic ductal adenocarcinoma (PDAC) patients who respond to treatment, but currently available biomarkers cannot reliably predict NAC response. This study aimed to determine the potential of a previously identified diagnostic and prognostic biomarker panel (i.e.

View Article and Find Full Text PDF
Article Synopsis
  • ALK-positive lung cancers exhibit molecular diversity and pose challenges due to treatment resistance, prompting the need for innovative strategies using ctDNA monitoring.
  • The ALKTERNATE pilot study analyzed alternating treatments of lorlatinib and crizotinib in patients resistant to previous ALK inhibitors, focusing on outcomes like treatment failure time, safety, and patient experiences.
  • Results showed that the alternating therapy was safe and effective for most participants, with an average treatment failure time of 10 months and overall survival of 23 months, indicating the importance of genetic factors in treatment response.
View Article and Find Full Text PDF
Article Synopsis
  • The study explores the use of an online clinical support tool designed to minimize judgment variability, or "noise," in prescribing radioactive iodine (RAI) for patients with differentiated thyroid cancer (DTC).
  • It involved applying the tool to 103 patients treated from 2021-2022 and comparing it to 393 patients treated from 2017-2021, showing significant reductions in RAI dosages for intermediate and high-risk patients.
  • The results indicate that the tool effectively reduces variability in treatment decisions without increasing recurrence rates, suggesting it's a beneficial resource for clinical practice in DTC management.
View Article and Find Full Text PDF

Phaeochromocytomas (PC) and paragangliomas (PG) are neural crest cancers with high heritability. Recent advances in molecular profiling, including multi-omics and single cell genomics has identified up to seven distinct molecular subtypes. These subtypes are defined by mutations involving hypoxia-inducible factors (HIFs), Krebs cycle, kinase and WNT signalling, but are also defined by chromaffin differentiation states.

View Article and Find Full Text PDF
Article Synopsis
  • Lymphocyte-rich inflammation of the esophagus is an emerging condition characterized by symptoms like difficulty swallowing and food blockages, often appearing similar to eosinophilic esophagitis during endoscopy.
  • Three main subtypes of this inflammation have been identified: lymphocytic, lichenoid, and lymphocyte-predominant esophagitis, which must be differentiated from other causes such as gastro-esophageal reflux and Candida infections.
  • The review highlights the need for systematic diagnostic criteria and recommends more research to understand the disease's progression and improve treatment strategies for affected patients.
View Article and Find Full Text PDF
Article Synopsis
  • Ampullary adenocarcinoma (AA) shows clinical and genetic diversity, and a new genomic classifier may improve patient classification beyond traditional methods, but it needs validation before being widely used.
  • A study involving 192 patients with AA assessed the accuracy of this genomic classifier against standard histology to see if it could predict survival outcomes.
  • Results indicated a 55% agreement between genomic and histological classifications; however, while histological subtypes did not predict survival, the genomic scores did correlate with survival probabilities, suggesting the genomic approach might be more effective.
View Article and Find Full Text PDF

Anaplastic thyroid cancer (ATC), a rare and highly aggressive malignancy, is characterized by an exceptionally poor prognosis, where the majority of patients present with extensive local invasion and/or distant metastases. 20-30% of ATCs harbor the BRAF-V600E mutation. Neoadjuvant BRAF-targeted therapy may have the potential to downstage and facilitate surgical resection for patients with locally advanced and unresectable primary tumors with BRAF mutation and may convey a survival advantage in those with metastatic disease.

View Article and Find Full Text PDF
Article Synopsis
  • Intraductal oncocytic papillary neoplasms (IOPNs) are now identified as distinct from intraductal papillary mucinous neoplasms (IPMNs), with limited information on their recurrence and survival outcomes.
  • A study analyzed outcomes of 415 patients with invasive IOPNs and adenocarcinoma from IPMN over a median of 6 years, finding similar recurrence rates between invasive IOPNs and ductal A-IPMN, but poorer survival compared to colloid A-IPMN.
  • The research concluded that invasive IOPNs behave like aggressive cancers, with adjuvant chemotherapy showing no significant impact on recurrence rates in any of the studied cancer types.
View Article and Find Full Text PDF

In this review, we explore the underlying molecular biology of medullary thyroid carcinoma (MTC) and its interplay with the host immune system. MTC is consistently driven by a small number of specific pathogenic variants, beyond which few additional genetic events are required for tumorigenesis. This explains the exceedingly low tumour mutational burden seen in most MTC, in contrast to other cancers.

View Article and Find Full Text PDF

Neoadjuvant therapy (NAT) has become routine in patients with borderline resectable pancreatic cancer. Pathologists examine pancreatic cancer resection specimens to evaluate the effect of NAT. However, an automated scoring system to objectively quantify residual pancreatic cancer (RPC) is currently lacking.

View Article and Find Full Text PDF
Article Synopsis
  • Hereditary mutant pheochromocytomas (PC) and paragangliomas (PG) are rare tumors that tend to metastasize unpredictably, prompting a study to better understand their genomic characteristics.
  • A multi-omic analysis of 94 tumors from 79 patients revealed distinct molecular profiles based on whether the tumors originated from sympathetic or parasympathetic cells, with specific alterations linked to metastatic behavior.
  • The study also identified high mutation loads, unusual genomic features, and mechanisms of resistance to DNA alkylating chemotherapies, enhancing the comprehension of these complex neuroendocrine tumors and their treatment responses.
View Article and Find Full Text PDF
Article Synopsis
  • The study examines the outcomes of different precursor epithelial subtypes of adenocarcinoma from intraductal papillary mucinous neoplasms (A-IPMN), focusing on clinical features and recurrence patterns among patients who underwent pancreatic surgery.
  • A total of 297 patients were analyzed, revealing that gastric, pancreatobiliary, and mixed subtypes have similar outcomes that are worse than the intestinal subtype in terms of recurrence and overall survival.
  • The research found that adjuvant chemotherapy specifically improved survival rates in the pancreatobiliary subtype, but not in gastric, intestinal, or mixed subtypes, indicating a potential area for further exploration in treatment strategies.
View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is characterized by increasing fibrosis, which can enhance tumor progression and spread. Here, we undertook an unbiased temporal assessment of the matrisome of the highly metastatic KPC (, , ) and poorly metastatic KPC (, , ) genetically engineered mouse models of pancreatic cancer using mass spectrometry proteomics. Our assessment at early-, mid-, and late-stage disease reveals an increased abundance of nidogen-2 (NID2) in the KPC model compared to KPC, with further validation showing that NID2 is primarily expressed by cancer-associated fibroblasts (CAFs).

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates factors affecting long-term survival and recurrence in patients with adenocarcinoma from intraductal papillary mucinous neoplasms, focusing on those who had pancreatic resection between 2010 and 2017 in Europe and Asia.
  • - It analyzed data from 288 patients, revealing that 48% experienced recurrence within about 98 months, with 35% remaining disease-free at the 5-year mark.
  • - Key negative predictors for long-term disease-free survival included multivisceral resection, tumor location in the pancreatic tail, poor differentiation, lymphovascular invasion, and perineural invasion, leading to the development of a predictive model with a good success rate.
View Article and Find Full Text PDF

Aims/hypothesis: Almost all beta cells contact one capillary and insulin granule fusion is targeted to this region. However, there are reports of beta cells contacting more than one capillary. We therefore set out to determine the proportion of beta cells with multiple contacts and the impact of this on cell structure and function.

View Article and Find Full Text PDF
Article Synopsis
  • RET mutations are found in 60% of medullary thyroid cancer cases and the drug selpercatinib shows significant effectiveness against it compared to older treatments.
  • A 22-year-old woman with metastatic medullary thyroid cancer improved with selpercatinib, but later developed lung nodules diagnosed as Langerhans cell histiocytosis, which had a rare BRAF mutation.
  • The authors suggest that the use of RET inhibitors like selpercatinib might cause dormant BRAF mutations to activate, leading to new cancers due to changes in the MAPK signaling pathway.
View Article and Find Full Text PDF

Objectives: There is a paucity of data regarding the use of neoadjuvant therapy in pancreatic body or tail ductal adenocarcinomas. Given the differing tumor biology and aggressive nature of pancreatic body or tail adenocarcinomas, patients presenting with these tumors may benefit from upfront resection.

Methods: A retrospective cohort study was performed analyzing patients who underwent distal pancreatectomy for pancreatic ductal adenocarcinoma between January 2013 and June 2022.

View Article and Find Full Text PDF